Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Microcystic lymphatic malformations

3 evidence topics · 2 sources

Epidemiology: microcystic lymphatic malformations

“an estimated more than 30,000 diagnosed patients in the U.S.” (opens the source at this quote in a new tab)

Epidemiology: lymphatic malformations with a cutaneous component

“lymphatic malformations with a cutaneous component (LMC)” (opens the source at this quote in a new tab)

“79,920 (CI 66,600–93,250)” (opens the source at this quote in a new tab)

“managed prevalence of 24.1 LMC patients per 100,000 population (CI 19.6/100,000–28.4/100,000).” (opens the source at this quote in a new tab)

Annual managed prevalence: distinction from total national prevalence

“It was not designed to estimate the total national prevalence of LMC” (opens the source at this quote in a new tab)